Financial Statements

Bayer Group Consolidated Statements
of Recognized Income and Expense

	3rd Quarter 2007	3rd Quarter 2008	First Nine Months 2007	First Nine Months 2008
€ million
Changes in fair values of derivatives designated as hedges and available-for-sale financial assets, recognized in stockholders’ equity	76	(268)	74	(148)
Changes in actuarial gains/losses on defined benefit obligations for pensions and other post-employment benefits and effects of the limitation on pension plan assets, recognized in stockholders’ equity	167	630	1,272	1,575
Exchange differences on translation of operations outside the euro zone, recognized in stockholders’ equity	(477)	387	(470)	(44)
Deferred taxes on valuation adjustments offset directly against stockholders’ equity	(184)	(115)	(615)	(438)
Changes due to changes in scope of consolidation	-	2	36	2
Revaluation surplus (IFRS 3)	-	0	-	6
Minority interest in partnerships, recognized in liabilities	(5)	(14)	(24)	(43)
Valuation adjustments recognized directly in stockholders’ equity	(423)	622	273	910
Income after taxes	1,178	278	4,645	1,621
Total income and expense recognized in the financial statements	755	900	4,918	2,531
of which attributable to minority interest	1	2	(1)	3
of which attributable to Bayer AG stockholders	754	898	4,919	2,528